United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

How Does Moderna Measure up to Bigger Rival Pfizer?

Pfizer Inc. (NYSE: PFE) and its German partner BioNTech SE (Nasdaq: BNTX) said they plan to provide 500 million doses of their COVID-19 vaccine to the U.S. government for donation to the "poorest nations." What Happened: The two companies said they will provide the 500 million doses of the vaccine to the U.S. government at a not-for-profit price.

Pfizer To Supply US 500 Million COVID-19 Doses To Be Donated To Poorest Nations

BioNTech SE

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies' COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. The government will, in turn, donate the Pfizer-BioNTech

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations

The US will buy 500 million more doses of the Pfizer COVID-19 vaccine to share through the global COVAX alliance for donation to 92 lower-income countries and the African Union over the next year, a person familiar with the matter said Wednesday. President Joe Biden was set to make the announcement Thursday in a speech.

US to buy 500M Pfizer vaccines to share globally

The US is to distribute half a billion shots of the Pfizer vaccine to 100 other countries.

America to give 500 million COVID jabs to poorer countries

Mastercard

Wells Fargo

Arlington Asset Investment

Amdocs

The S&P 500 traded slightly down Monday as the benchmark index struggled to continue its upward push to new all-time highs after last week's overall excellent performance. Meanwhile, the Nasdaq Composite managed to score 0.5% gains on the day as techs trended marginally higher.

Wells Fargo & Company And Mastercard Rated Trending Stocks Today

Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.

Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20

AbbVie

Looking for some extra income in this market? Consider these two blue-chip stocks.

2 High-Yield Dividend Stocks for 2021

The FDA has approved Pfizer Inc's (NYSE: PFE) Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) to prevent invasive disease and pneumonia caused by the 20 common strains of Streptococcus pneumonia in adults. Following today's FDA approval, the vaccine will now go to the U.S. Centers for Disease Control and Prevention (CDC).

FDA Clears Pfizer's Prevnar 20 Conjugate Vaccine For Adults

It has to do with getting a step ahead of the coronavirus.

What Investors Need to Know From Pfizer's Earnings Report

Long-term PFE stock holders might be wary of dividend-cut talk, but a recent announcement should clear up any confusion on the matter. The post Pfizer Is Still One of the Healthcare Sector's Best Dividend Yielders appeared first on InvestorPlace.

Pfizer Is Still One of the Healthcare Sector's Best Dividend Yielders

The market size could even be bigger. But the drugmakers still have some hurdles to jump.

Why Pfizer and Moderna Could Soon Be Big Winners in a New $22 Billion Market

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today's FDA approval, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) is

U.S. FDA Approves PREVNAR 20™, Pfizer's Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) will begin testing its COVID-19 vaccine in a bigger group of children under age 12 after selecting a lower dose shot in an earlier stage of the trial. The study will enroll up to 4,500 children at more than 90 clinical sites, Reuters reported.

Pfizer/BioNTech Initiates COVID-19 Vaccine Trial In Children Below 12 Years: Reuters

COVID-19 vaccines could be available for US children as young as 6 months old by the fall, Pfizer and Moderna told the New York Times. Pfizer announced on Tuesday that it is starting to test its COVID-19 vaccine in kids aged 5 to 12, and told The Times that it would likely start testing the shot in kids as young as 6 months old in the next few weeks.

COVID-19 vaccines could be available for kids as young as 6 months old starting this fall

Bristol-Myers

If it's steadiness you're after, these two healthcare giants have shown they can perform during a pandemic and beyond.

2 Blue Chips to Buy Now for a Bear Market

Inovio Pharmaceuticals

Novavax

Vaxart

These Vaccine Latecomers Could Still Win Big. Here's How

Pretty well, although it's not an apples-to-apples comparison between the two studies.

How Did Moderna's COVID Vaccine Results in Teens Stack Up Against Pfizer's?

The need for incentives for vaccination now could point to lower vaccination rates going forward.

Could COVID Vaccination Incentives Hint at Future Problems for Pfizer and Moderna?

Pfizer still has good upside, especially if the dividend yield falls. PFE stock could be worth $53.33 given a dividend increase, a 3.0% dividend yield and return to buybacks.

Pfizer Stock Still Has Good Upside, Especially If the Dividend Yield Falls

The COVID-19 vaccine developed jointly by Pfizer and BioNTech has been approved for 12 to 15-year-olds in the U.K, the Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday. More than 2,000 children were involved in the clinical trial to determine the safety of the Pfizer-BioNTech vaccine, the chairman of the Commission on Human Medicines said.

Pfizer-BioNTech Covid-19 vaccine approved for 12 to 15-year-olds in the U.K.

The CDC is monitoring rare side effects and stressed the benefits of vaccination far outweigh any possible risks.

Heart Inflammation Reported In Seven U.S. Teens Following Pfizer Covid Vaccine, Study Shows

It has to do with individuals who haven't yet been vaccinated.

This 1 Factor May Mean Bigger Vaccine Orders for Pfizer and Moderna

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Pfizer (PFE) Down 3% Since Last Earnings Report: Can It Rebound?

Bahrain is fighting a fierce Covid surge despite having one of the highest vaccination rates in the world.

News for Pfizer Stock (PFE)